GRIP: Maximum Isometric Grip Strength Assessed with Three Different Hand-held Dynamometers
Launched by JOHANNES SCHERR · Oct 24, 2022
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
The GRIP clinical trial is studying how to measure grip strength using three different devices to find out which one works best. Grip strength is an important way to assess upper body strength in both adults and children, and the current standard device is called the JAMAR Hydraulic Hand Dynamometer. However, this trial aims to compare this standard device with two other devices—the JAMAR Smart Hand Dynamometer and the Martin Vigorimeter—to see if they are just as reliable and accurate. The researchers also want to gather reference values for grip strength based on different age groups, genders, and activity levels.
To participate in the trial, volunteers should be between 10 and 64 years old and have a healthy body weight (a BMI less than 30). If a participant is under 14, a parent or guardian must give consent. However, individuals with certain injuries, diseases affecting their arm strength, or cognitive impairments are not eligible to join. Participants in this trial can expect to engage in simple grip strength tests and help researchers gather valuable information that could improve how grip strength is measured in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria Part 1:
- • Male and female volunteers with age 18-64 years
- • Body mass index \< 30 kg/m2
- • Informed consent signed
- Inclusion Criteria Part 2:
- • Male and female volunteers with age ≥ 10 years
- • Informed consent signed (if age \< 14 years, signed by parents or legal guardians)
- Exclusion Criteria Part 1 and 2:
- • Disease or injury (e.g., musculoskeletal or neurological) that could affect upper extremity strength
- • Physical impairment of the upper extremity (visible swelling or the presence of a splint or cast)
- • Acute pain or infection
- • Cognitive impairment (inability to understand and/or follow directions)
- • Insufficient language of the German language
About Johannes Scherr
Johannes Scherr is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapies and treatment strategies, Scherr collaborates with healthcare professionals and research institutions to facilitate the development and execution of clinical trials. Emphasizing rigorous scientific standards and ethical practices, the organization aims to enhance the understanding of diseases and contribute to the discovery of effective solutions that address unmet medical needs. Through strategic partnerships and a patient-centered approach, Johannes Scherr is poised to make significant contributions to the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zürich, , Switzerland
Patients applied
Trial Officials
Johannes Scherr, Prof Dr med
Principal Investigator
Balgrist University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials